Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Despite concerns about excessive weight loss, retatrutide will be an important addition for obesity patients when it's approved
Many people who are interested in tirzepatide also have high blood pressure, insulin resistance, elevated cholesterol, prediabetes, type 2 diabetes, or other metabolic health concerns
CagriSema, the combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, produced an estimated mean body weight reduction of 20.4% compared to 3.0% with placebo
Sabeen Munib Spectrum Skin Clinic, Irvine
Status Still investigational Retatrutide has Phase 3 data but no FDA-approved prescribing label yet
Most patients average about $80$135 per month during the initial treatment phase, depending on whether semaglutide or tirzepatide is prescribed and how long the medication lasts at the prescribed dose
US$ 20.31
US$ 28.69
US$ 21.57
US$ 21.46
